Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 Knobloch Lecture

Pan-American Collaborative Retina Study Group (PACORES)

Research output: Contribution to journalReview article

Abstract

The advent of intravitreal anti-vascular endothelial growth factor (anti-VEGF) medications has revolutionized the treatment of diabetic eye diseases. Herein, we report the outcomes of clinical studies carried out by the Pan-American Collaborative Retina Study Group (PACORES), with a specific focus on the efficacy of intravitreal bevacizumab in the management of diabetic macular edema and proliferative diabetic retinopathy. We will also discuss the use of intravitreal bevacizumab as a preoperative, adjuvant therapy before vitrectomy for proliferative diabetic retinopathy.

Original languageEnglish (US)
Pages (from-to)36-39
Number of pages4
JournalAsia-Pacific journal of ophthalmology (Philadelphia, Pa.)
Volume7
Issue number1
DOIs
StatePublished - Jan 1 2018

Keywords

  • bevacizumab
  • diabetic macular edema
  • intravitreal injections
  • proliferative diabetic retinopathy
  • tractional retinal detachment

ASJC Scopus subject areas

  • Ophthalmology

Fingerprint Dive into the research topics of 'Intravitreal Bevacizumab in Diabetic Retinopathy. Recommendations from the Pan-American Collaborative Retina Study Group (PACORES): The 2016 Knobloch Lecture'. Together they form a unique fingerprint.

  • Cite this